Shots:
- The US FDA has approved Nufymco (ranibizumab-leyk), an interchangeable biosimilar of Lucentis, with Zydus serving as its commercialization partner in the US
- Nufymco is an interchangeable Lucentis biosimilar developed by Formycon, approved for the treatment of wet AMD, diabetic macular edema, diabetic retinopathy, retinal vein occlusion-related macular edema, and myopic choroidal neovascularization
- Zydus secured exclusive US and Canada rights to Formycon’s Keytruda biosimilar FYB206
Ref: Formycon| Image: Formycon |Press Release
Related News: Formycon Partners with Zydus to Commercialize FYB206 (Biosimilar, Keytruda) in the US and Canada
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
